Tebotelimab is a humanized bispecific DART molecule targeting PD-1 and LAG-3, with immunomodulatory and antineoplastic activities. It enhances T-cell activation by blocking both checkpoints and has shown anti-tumor activity, including in combination with anti-HER2 therapies. M.W 165.68 kDa